HTB homepage • Conference reports • Articles by subject • Subscribe February 2022 Contents Editorial HTB: no. 1/2 (January/February 2022) i-Base appeal: please support i-Base with £5 or £10 a month Conference reports CROI 2022 to only be virtual: programme online Antiretrovirals US FDA approves 2-monthly dosing option for long-acting injectable cabotegravir/rilpivirine Gilead to pay $1.25 billion plus royalties to ViiV Healthcare for bictegravir infringing on dolutegravir patent Guidelines BHIVA interim guidance on long-acting cabotegravir and rilpivirine injections Coinfections and complications HIV-associated reductions in telomere length are stopped by effective ART Drug resistance Drug resistance profile of integrase inhibitors when treating HIV-2 Other news EACS HIV Summer School 2022: Applications are open COVID-19: investigational drugs UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19 COVID-19: guidelines IDSA update COVID-19 guidelines (January 2022) Job vacancies i-Base vacancy: HIV treatment advocate and information officer PDFs HTB: no. 1/2 – plus HIV and COVID-19 (7 February 2022) HTB homepage • Conference reports • Articles by subject • Subscribe